Skip to main content
SpringerLink
Log in

Versorgungsforschung bei niedergelassenen Pneumologen

Wie praxisrelevant sind die GOLD-Empfehlungen für den ambulanten Alltag bei COPD?

  • aktuell
  • Published:
Pneumo News Aims and scope

Die GOLD-Empfehlungen stellen den evidenzbasierten State of the Art der Diagnostik und Therapie bei chronisch obstruktiver Lungenerkrankung (COPD) vor. Wie weit sie im Praxisalltag umgesetzt werden, ist aber wenig bekannt. Daher wurde eine deutschlandweite Erhebung bei niedergelassenen Pneumologen initiiert*a. Wichtige Erkenntnisse daraus: Die Implementierung scheint oft an der Praktikabilität zu scheitern. Die Ärzte sind bei Symptomüberwachung und Adhärenzkontrolle sehr gefragt. Und: Die Kombination aus LAMA und LABA gehört bereits zur Verordnungsroutine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

Literatur

  1. Global Initiative for Chronic Obstructive Lung Disease, Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease, 2015. Online abgerufen am 23.7.2015 unter http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Apr2.pdf.

  2. Lopez-Campos JL, Calero C, Lopez-Ramirez C, et al. Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium. Patient Preference and Adherence 2015; 9:95–104

    Article  PubMed Central  PubMed  Google Scholar 

  3. Koblize V, Pecen LL, Zatloukal J, et al. Real-Life GOLD 2011 Implementation: The Management of COPD Lacks Correct Classification and Adequate Treatment. PLOS ONE 2014; 9(11):e111078

    Article  Google Scholar 

  4. Papala M, Kerenidi N, Gourgoulianis KI. Everyday clinical practice and its relationship to 2010 and 2011 GOLD guideline recommendations for the management of COPD. Primary Care Respiratory Journal 2013; http://dx.doi.org/10.4104/pcrj.2013.00073

  5. Maio S, Baldacci S, Martini F, et al. COPD management according to old and new GOLD guidelines: an ob-servational study with Italian general practitioners. Curr Med Res Opin 2014; 30(6):10331042

    Article  Google Scholar 

  6. Geiser T. COPD im GOLD-Fieber oder das neue ABC der COPD. Schweiz Med Forum 2014;14(3):45–46

    Google Scholar 

  7. Seemungal TAR, Hurst JR, Wedzicha JA. Exacerbation rate, health status and mortality in COPD — a review of potential interventions. International Journal of COPD 2009; 4:203–223

    Article  PubMed Central  PubMed  Google Scholar 

  8. Soler-Cataluna JJ, Martinez-Garcia MA, Sánchez PR, et al. Severe acute exacerbations and mortality in pa-tients with chronic obstructive pulmonary disease. Thorax 2005; 60:925–931

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Calverley PMA, Leese A, Towse L, et al. Effect of tiotropium bromide on circadian variation in airflow limita-tion in chronic obstructive pulmonary disease. Thorax 2003; 58:855–860

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009; 25(8):2043–2048

    Article  PubMed  Google Scholar 

  11. Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross- sectional study. Eur Respir J 2011; 37:264–272

    Article  CAS  PubMed  Google Scholar 

  12. Roche N, Chavanne NH, Miravittles M. COPD symptoms in the morning: impact, evaluation and manage-ment. Resp Res 2013; 14:112

    Article  Google Scholar 

  13. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011; 364(12):1093–1103

    Article  CAS  PubMed  Google Scholar 

  14. Decramer DL, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med 2013; 1:524–533

    Article  CAS  PubMed  Google Scholar 

  15. Cazolla M, Brusasco V, Centanni S, et al. Project PriMo: Sharing principles and practices of bronchodilator therapy monitoring in COPD A consensus initiative for optimizing therapeutic appropriateness among Italian specialists. Pulmonary Pharmacology & Therapeutics 2013; 26:218–228

    Article  Google Scholar 

  16. Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012; 64:450–504

    Article  CAS  PubMed  Google Scholar 

  17. Cazolla M, Tashkin DP. Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. COPD 2009; 6(5):404415.

    Google Scholar 

  18. Van Noord JA, Buhl R, Laforce C, Martin C, Jones F, Dolker M, Overend T. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 2010; 65:1086–91

    Article  PubMed  Google Scholar 

  19. Singh D. New combination bronchodilators for COPD: current evidence and future perspectives Br J Clin Pharmacol Nov 6, 2014; DOI:10.1111/bcp.12545

  20. Vogelmeier C, Kardos P, Harari S, et al. Formoterol mono- and combination therapy with tiotropium in pa-tients with COPD: A 6-month study. Respiratory Medicine 2008; 102:1511–1520

    Article  PubMed  Google Scholar 

  21. Tashkin DP, Pearle J, Iezzoni D, Varghese ST. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 2009; 6(1):1725

    Article  Google Scholar 

  22. Tashkin DP, Littner M, Andrews CP, et al. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: A placebo-controlled trial. Respiratory Medicine 2008; 102:479–487

    Article  PubMed  Google Scholar 

  23. Tashkin DP, Donahue JF, Mahler DA, et al. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respiratory Medicine 2009; 103:516e524

    Google Scholar 

  24. Hanania NA, Boota A, Kerwin E, et al. Efficacy and Safety of Nebulized Formoterol as Add-on Therapy in COPD Patients Receiving Maintenance Tiotropium Bromide. Drugs 2009; 69 (9):1205–1216

    Article  CAS  PubMed  Google Scholar 

  25. Van Noord JA, Aumann JL, Janssens E, et al. Effects of Tiotropium With and Without Formoterol on Airflow Obstruction and Resting Hyperinflation in Patients With COPD. CHEST 2006; 129:509–517

    Article  PubMed  Google Scholar 

  26. Van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26:214–222

    Article  PubMed  Google Scholar 

  27. Berton DC, Reis M, Siqueira ACB, et al. Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD. Respir Med 2010; 104:1288e1296

    Google Scholar 

  28. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013; 42:1484–1494

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). ERJ Express. Published on January 8, 2015 as DOI: 10.1183/09031936.00136014

  30. D’Urzo AD, Rennard SI, Kerwin EM, et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respira-tory Research 2014; 15:123

    Article  Google Scholar 

  31. Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/ formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulmonary Medicine 2014; 14:178

    Article  PubMed Central  PubMed  Google Scholar 

  32. Bateman ED, Chapman KR, Singh D, et al. Respir Res 2015; 16:92. doi: 10.1186/s12931-015-0250-2.

  33. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. N Engl J Med 2007; 356:775–789

    Article  CAS  PubMed  Google Scholar 

  34. Singh S, Loke YK. An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2010; 5:189–195

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Singh S, Loke YK. Risk of pneumonia associated with long-term use of inhaled corticosteroids in COPD: A critical review and update. Curr Opin Pulm Med 2010; 16(2):118–122

    Article  PubMed Central  PubMed  Google Scholar 

  36. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD. N Engl J Med 2014; 371(14):1285–1294

    Article  PubMed  Google Scholar 

  37. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax 2008; 63: 831–838

    Article  CAS  PubMed  Google Scholar 

  38. Lareau SC, Yawn BP. Improving adherence with inhaler therapy in COPD. national Journal of COPD 2010; 5:401–406

    Article  Google Scholar 

  39. Bryant J, McDonald VM, Boyes A, et al. Improving medication adherence in chronic obstructive pulmonary disease: a systematic review. Respiratory Research 2013; 14:109

    Article  PubMed Central  PubMed  Google Scholar 

  40. Sanduzzi A, Balbo P, Candoli P et al. COPD: adherence to therapy. Multidisciplinary Respiratory Medicine 2014; 9:60. http://www.mrmjournal.com/content/9/1/60

    Article  PubMed Central  PubMed  Google Scholar 

  41. Van der Palen J. Genuair® in chronic obstructive pulmonary disease: a novel, user-friendly, multidose, dry-powder inhaler. Ther Deliv 2014; 5(7):795–806

    Article  Google Scholar 

  42. Chrystyn H, Small M, Milligan G, et al. Impact of patients’ satisfaction with their inhalers on treatment com-pliance and health status in COPD. Respiratory Medicine 2014; 108(2):358–365

    Article  PubMed  Google Scholar 

  43. Chrystyn H. Do patients show the same level of adherence with all dry powder inhalers? J Clin Pract 2005; 59(149):19–25

    Article  Google Scholar 

  44. Restrepo RD, Alvarez MT, Wittnebel LD. Medication adherence issues in patients treated for COPD. International Journal of COPD 2008; 3(3):371–384

    PubMed Central  PubMed  Google Scholar 

  45. Toy EL, Beaulieu NU, McHale JM. Treatment of COPD: Relationships between daily dosing frequency, ad-herence, resource use, and costs. Respiratory Medicine 2011;105(3):435–441

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Colonnaden 72, 20354, Hamburg, Deuschland

    Björn Laudahn (Schwerpunktpraxis Colonnaden)

  2. Mehrower Allee 20, 12687, Berlin, Deuschland

    Sören Schmidtmann (Praxis Dr. Schmidtmann)

Authors
  1. Björn Laudahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sören Schmidtmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Björn Laudahn.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Laudahn, B., Schmidtmann, S. Wie praxisrelevant sind die GOLD-Empfehlungen für den ambulanten Alltag bei COPD?. Pneumo News 7, 53–59 (2015). https://doi.org/10.1007/s15033-015-0233-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15033-015-0233-5

Search

Navigation